How to Assess Target–Drug Opportunities Before Starting BD Due Diligence
A useful target–drug opportunity assessment helps a team decide whether an asset deserves deeper diligence—not whether to license it. This guide shows how an AI Skill connects development status, differentiation, rights signals, and evidence gaps using KRAS G12D therapies for pancreatic cancer as an example.
The example below is a focused opportunity screen from a real public-evidence run on systemic KRAS G12D therapies in advanced or metastatic pancreatic ductal adenocarcinoma. It shows the shortlist and the conditions that still need diligence.
KRAS G12D in PDAC: evidence for a focused diligence shortlist
The public evidence supports considering targeted asset diligence, but not an asset selection or transaction decision. Clinical comparability, differentiation, rights, CMC, and patent position remain decisive.
| Asset | Public development signal | Why it merits review |
|---|---|---|
| INCB161734 Incyte | Company-confirmed Phase 3 PDAC program | Sets a late-stage clinical and differentiation benchmark. |
| Zoldonrasib Revolution Medicines | Company-confirmed Phase 3 RASolute 305 | Raises the competitive-timing and evidence comparison bar. |
| VS-7375 / GFH-375 Verastem / GenFleet | Registration-directed Phase 2 program and disclosed collaboration | Shows an active partnering route; territory and economic terms still need verification. |
Screening conclusion: the public evidence supports a focused diligence shortlist. Advancement should depend on clinically comparable differentiation, available target rights, a credible resistance strategy, and manageable CMC risk.
What this supports
Prioritizing which programs and questions deserve focused diligence.
What it does not decide
Asset selection, licensing availability, valuation, patent clearance, or transaction terms.
Why this is a reasonable screening result: three independently reported programs show that the target–indication space is clinically active, while the Verastem–GenFleet collaboration makes rights structure a practical diligence question. The evidence is strong enough to prioritize review, but not comparable enough to select an asset.
Define the indication, modality, territory, deal purpose, and the conditions that would justify deeper diligence.
What a target–drug opportunity assessment should clarify
The report should help a team decide whether the available evidence supports stopping, watching, or preparing focused diligence. It should compare biological rationale, clinical maturity, modality fit, sponsor position, differentiation, rights signals, development feasibility, and evidence quality—not simply count pipeline records.
Why pipeline counts can mislead
Broad searches can return aliases, duplicate assets, multiple indications, inactive programs, investigator-led trials, and translational studies that are not licensable programs. Those records establish coverage, but they do not show that an opportunity is attractive or available.
Why Patsnap matters for this task
Patsnap life-sciences intelligence connects target, drug, disease, trial, literature, patent, and competitive records that are otherwise easy to review as disconnected lists. These links matter because aliases, sponsors, stages, indications, and regional rights can change the apparent opportunity. The Skill applies a consistent BD review method to that evidence; the data improves traceability but does not independently validate an asset or transaction.
How the Skill builds the opportunity screen
The Skill narrows a broad evidence set into a decision-oriented shortlist while keeping incomplete or non-comparable evidence visible.
Prepare, install, and run
What you need to provide: the target or asset, modality, indication, treatment setting, territory, deal purpose, time horizon, comparator set, and the clinical, rights, CMC, and commercial conditions that matter to your team.
What the Skill keeps consistent: entity normalization, evidence dates, source roles, comparison criteria, uncertainty, and measurable go/no-go conditions.
Assess business-development opportunities for systemic KRAS G12D therapies in advanced or metastatic pancreatic ductal adenocarcinoma. Identify the most decision-relevant assets and sponsors, verify public development status, compare differentiation signals, note disclosed rights activity, and recommend whether to proceed to targeted diligence. Separate verified facts, inference, and unresolved diligence questions.Review the scope and any confidential inputs before the run. Refresh dynamic development, rights, patent, and regulatory evidence at the decision date.
How to use the result
Use the opportunity assessment to decide which target–drug combinations deserve deeper diligence, which assumptions remain unsupported, and what evidence should unlock the next BD or portfolio decision.
Before acting, verify target identity and biology, asset ownership, development status, clinical and regulatory evidence, patent and exclusivity position, transaction context, competitive alternatives, and the exact indication and geography. Treat a missing deal, trial, patent, or scientific record as an evidence gap—not as proof of absence or low risk.
The report supports prioritization and diligence planning within its stated scope. It does not establish clinical value, commercial attractiveness, ownership, freedom to operate, deal availability, or an investment decision.
Connect your agent to life-sciences research tools
Explore target, drug, trial, scientific, regulatory, and patent research paths when the next diligence question needs current structured evidence.
Frequently asked questions
Are database asset counts the same as unique pipeline counts?
No. Asset aliases, sponsors, indications, trial records, and inactive programs must be resolved before a count can support comparison.
Can the Skill estimate deal value?
Not from public screening evidence alone. Valuation requires rights, economics, probabilities, comparables, internal assumptions, and financial review.
Does the Skill replace clinical, patent, or legal diligence?
No. It organizes evidence and diligence questions; qualified reviewers must verify the claims and assumptions that affect a material decision.
